Senesco Technologies, Inc. SNT
announced today that the combination of lenalidomide and SNS01-T, the subject
of Senesco's on-going multiple myeloma clinical study, performs better than
either treatment alone in mouse xenograft models of human mantle cell
lymphoma.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in